Last time I'm emailing you about this

Over the last week or so, my colleagues and I have asked you on multiple occasions to register for a special webinar event, which aired for the first time ever this past Thursday. You are receiving this email because you subscribed to Wealth Daily. [Click here]( to manage your e-mail preferences. [Wealth Daily logo] Last time I'm emailing you about this [Jason Stutman Photo] By [Jason Stutman]( Written Apr. 20, 2019 Over the last week or so, my colleagues and I have asked you on multiple occasions to register for a special webinar event, which aired for the first time ever this past Thursday. We’ve been pushing this event hard, so if you feel like we’ve been badgering you, understand it’s for good reason. If you were among those with the foresight to register last week and catch the webinar, you already know what that reason is: After years of preparation, we’ve developed a one-of-a-kind trading system that predicts double- and triple-digit stock rallies on a regular basis. It’s the kind of system that hedge fund managers and Wall Street traders drool over, but the fact is, we’re not selling it to them... Instead, we’ve designed it for Main Street investors like you. Bank 1,000% on the Death of Comcast America’s most hated cable company is standing on its last leg. And it’s not because of terrible customer service or mediocre products. It’s because of a technological shift that’s scheduled to start in late-2018. It's a shift that could earn you 1,000% gains as three companies bring down big cable. [Click here for their ticker symbols.]( Now, if you didn’t have time to catch the webinar event and you’re wondering how this system works, I can lay it out pretty quickly right here: We target major impact events in biotechnology and aim to profit from the price swings that follow. In other words, we’re looking for upcoming FDA approvals and the release of critical top-line trial data. That’s when the market gets a first look at information that will make a small development-stage biotech stock sink or swim. We’re talking about sudden market swings like: - 669% on Amarin Corporation (NASDAQ: AMRN) in just a few short weeks - 190% on ProQR Therapeutics (NASDAQ: PRQR) in just one week - 98% on Reata Pharmaceuticals (NASDAQ: RETA) in less than a month - 314% on Amarin Corporation (NASDAQ: AMRN) in less than one day - 125% on MacroGenics (NASDAQ: MGNX) in a matter of hours - Even a stunning 3,278% return on Aquinox Pharmaceuticals (NASDAQ: AQXP) in just one day of trading. Now, as a fair warning, understand that this kind of strategy isn’t for the faint of heart. This is for serious traders who are looking for HUGE stock swings in very short periods of time. Our typical trade runs for about a week and half, and we average about two trades every month. We work off a calendar of scheduled events, which allows us to reduce our time risk in the market and pinpoint the best opportunities to profit. We accomplish all this by leveraging insight from the most prominent experts in the field. We pay big money for access to a network of scientists and doctors who are contractually obligated to analyze drug trial data for us on the fly. Not only that, but this network breaks down approval chances for individual drug trials. This way we know our chance of success on a trade before we enter in. For late-stage drug trials pending approval, we issue trades only when “Chance of Success” is above 90%. This allows us to invest with confidence and catch quick stock returns at relatively low risk. Not every trade will go our way, but we’ve already locked in multiple double-digit winners in early beta testing. Simply put, this is easily the most profitable trading system I’ve come across in my career, which is why I’m so excited to share it with you. 3 Biotech Stocks Set to Soar The biotech sector just had its best month in more than two years... Which is why major media outlets like CNBC are saying: "Biotech is breaking out." They’re not bluffing, either. The 10 biggest biotech companies have ALL shot up in price since the start of 2019. [Click here to see which three stocks are next.]( Originally, we were going to limit the event to those of you who registered, but many have reached out saying they were unable to catch the event when it originally aired Thursday afternoon. Given that demand, I’ve included a temporary link to a recording of the webinar below, which will grant access to this new trading system. Now, I can’t say exactly how long we will keep this link live, but I can say that it will not be active for much time. The reason for this is that we have to keep seats limited. Too many traders can make these stocks go flying due to their small size, and it isn’t our intention to move the market with our trade alerts. That said, [we’re capping orders from this offer at 100. First come, first served](. I look forward to seeing you on the inside. Until next time, [JS Sig] Jason Stutman [follow basic]( [@JasonStutman on Twitter]( Jason Stutman is Wealth Daily's senior technology analyst and editor of investment advisory newsletters Technology and Opportunity and The Cutting Edge. His strategy for building winning portfolios is simple: Buy the disruptor, sell the disrupted. Covering the broad sector of technology and occasionally dabbling in the political sphere, Jason has written hundreds of articles spanning topics from consumer electronics and development stage biotechnology to political forecasting and social commentary. Outside the office Jason is a lover of science fiction and the outdoors, and an amateur squash player at best. He writes through the lens of a futurist, free market advocate, and fiscal conservative. Jason currently hails from Baltimore, Maryland, with roots in the great state of New York. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [How to Increase Your Chance of Success with Biotech Stocks]( [Information Is Your Best Investment Tool]( [What Makes an Expert?]( [Who Profits from High Prescription Drug Prices?]( [How I Trade Options]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletterwealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2019, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.